8-K: Septerna's SEP-631 Shows Positive Phase 1 Data, Advances to Phase 2

Septerna, Inc. announced positive Phase 1 clinical trial results for SEP-631, an oral drug for mast cell-driven diseases, and outlined its Phase 2 development strategy.

Summary

• SEP-631, an oral MRGPRX2 negative allosteric modulator (NAM), demonstrated positive results in its Phase 1 clinical trial in healthy volunteers.
• The drug was well-tolerated across all doses, with an adverse event profile comparable to placebo and no severe or serious adverse events.
• SEP-631 exhibited a pharmacokinetic (PK) profile supporting convenient once-daily oral dosing, including a half-life of approximately 24 hours and no clinically meaningful food effect.
• Pharmacodynamic (PD) activity showed robust suppression of icatibant-induced skin wheal formation, with complete inhibition at doses as low as 10 mg once daily for a 10 µg/mL icatibant challenge.
• Dose-dependent inhibition was observed for a 100 µg/mL icatibant challenge, with near to complete inhibition achieved at 90 mg and 200 mg once daily.
• These findings provide clinical proof-of-mechanism for SEP-631's potent target engagement and functional blockade of MRGPRX2 signaling in humans.
• Septerna plans to initiate a Phase 2b clinical trial for SEP-631 in chronic spontaneous urticaria (CSU) in the second half of 2026, pending completion of long-term toxicology studies.
• An open-label study in chronic inducible urticaria (CIndU), specifically in patients with symptomatic dermatographism, is also planned following the CSU study initiation.
• The company is evaluating SEP-631 for additional mast cell-driven diseases, including atopic dermatitis, interstitial cystitis, migraine, and asthma.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development, given the successful Phase 1 results, clear clinical proof-of-mechanism, and defined path into Phase 2 for a significant unmet medical need, supported by a solid cash runway.

Positives

• SEP-631 was well-tolerated across all doses studied in the Phase 1 trial, with an adverse event profile comparable to placebo.
• No severe or serious adverse events, nor clinically meaningful laboratory or ECG abnormalities were reported.
• The drug demonstrated a pharmacokinetic profile supportive of convenient once-daily oral dosing, with an approximate 24-hour half-life.
• No clinically meaningful effect of food on SEP-631 exposure, allowing for dosing without food restrictions.
• SEP-631 produced robust suppression of icatibant-induced skin wheal formation, achieving complete inhibition at doses as low as 10 mg once daily.
• The results provide clinical proof-of-mechanism for SEP-631's insurmountable negative allosteric modulator (NAM) action on MRGPRX2.

Risks

• Product candidates, including SEP-631, may not successfully enter or advance through clinical trials, facing uncertainties related to INDs and other regulatory approvals.
• Clinical development outcomes could include unexpected safety or efficacy findings.
• Results from preclinical studies, such as the ongoing long-term toxicology studies for SEP-631, or current clinical studies may not be predictive of future clinical outcomes.
• There are risks related to the timing of initiating clinical studies and the future availability of clinical data.
• The scope of protection Septerna is able to establish and maintain for intellectual property rights covering its Native Complex Platform and product candidates may be insufficient.

Future Outlook

Septerna expects to continue advancing SEP-631, with plans to initiate a Phase 2b clinical study in chronic spontaneous urticaria (CSU) in the second half of 2026, contingent on successful completion of long-term preclinical toxicology studies. The company anticipates SEP-631 will provide a convenient once-daily oral treatment option for patients with CSU and other mast cell-driven diseases, leveraging its proprietary Native Complex Platform. Septerna also plans to explore additional high-need indications where MRGPRX2 biology is implicated, such as atopic dermatitis, interstitial cystitis, migraine, and asthma.

Management Comments

• Jae Kim, M.D., chief medical officer, stated: "Importantly, the robust inhibition of icatibant-induced wheal formation observed is consistent with the differentiated insurmountable NAM mechanism we characterized preclinically and provides clinical proof-of-mechanism for the MRGPRX2 pathway."
• Jae Kim, M.D., chief medical officer, also commented: "Overall, we believe the strength and consistency of these results position SEP-631 as a potentially differentiated oral treatment for patients living with mast cell-driven diseases."
• Jae Kim, M.D., chief medical officer, added: "With a clear path into Phase 2 development in chronic spontaneous urticaria, we are focused on translating this early validation into meaningful outcomes for patients and exploring additional high-need indications where MRGPRX2 biology is implicated."

Industry Context

StockSavvy.ai notes that Septerna's positive Phase 1 data for SEP-631 highlights the potential of its Native Complex Platform in pioneering new approaches to GPCR drug discovery. Targeting MRGPRX2, a key regulator of mast cell degranulation, positions SEP-631 in the growing market for treatments of allergic and inflammatory diseases. The advancement to Phase 2 for chronic spontaneous urticaria (CSU) and exploration of other mast cell-driven indications like atopic dermatitis and asthma, addresses areas with high unmet medical needs, potentially offering a differentiated oral treatment option in a landscape often dominated by injectables or less specific therapies.

Comparison to Industry Standards

• The filing describes SEP-631 as having a 'potentially differentiated oral treatment' and 'potential best-in-class profile' due to its insurmountable negative allosteric modulator (NAM) mechanism, which completely closes the agonist binding pocket of MRGPRX2.
• The company aims to provide a convenient once-daily oral treatment option, which could offer an advantage over existing therapies for CSU, where approximately 40% of patients are refractory to first-line high-dose antihistamines and there is a high unmet need for safe second-line oral options.
• While specific comparable companies or projects are not named, the focus on an oral small molecule for GPCRs, particularly with a novel mechanism like insurmountable NAM, suggests an attempt to differentiate from current standards of care or other pipeline candidates in mast cell-driven diseases.

Stakeholder Impact

• **Shareholders:** Positive Phase 1 results and advancement to Phase 2 could increase investor confidence and potentially lead to stock price appreciation, especially given the large market opportunities in mast cell-driven diseases.
• **Patients:** Offers hope for a new, convenient oral treatment option for chronic spontaneous urticaria (CSU) and other mast cell-driven diseases, particularly for those refractory to current therapies.
• **Employees:** Continued positive clinical development strengthens the company's pipeline and strategic direction, potentially fostering job security and growth opportunities.
• **Regulatory Authorities:** Successful progression through clinical trials will require ongoing engagement and approvals from regulatory bodies like the FDA, impacting future market access.

Next Steps

• Initiate a Phase 2b clinical trial of SEP-631 in chronic spontaneous urticaria (CSU) in the second half of 2026, following completion of ongoing long-term toxicology studies.
• Pursue an open-label study in chronic inducible urticaria (CIndU), specifically in patients with symptomatic dermatographism, after the CSU study initiation.
• Continue evaluating additional mast cell-driven diseases with high unmet medical need and evidence of MRGPRX2 expression, including atopic dermatitis, interstitial cystitis, migraine, and asthma, for further assessment.
• Host a conference call and webcast on March 2, 2026, at 8:00 a.m. ET to discuss the Phase 1 results and initial Phase 2 development strategy for SEP-631.

Key Dates

Recommendation

The positive Phase 1 data for SEP-631, demonstrating strong safety, favorable pharmacokinetics, and clear clinical proof-of-mechanism, significantly de-risks the program. The outlined Phase 2 development strategy for chronic spontaneous urticaria (CSU) and other mast cell-driven diseases targets large markets with high unmet needs. Septerna's proprietary Native Complex Platform shows validation, and the company's strong cash position into 2029 provides ample runway for continued development. This combination of clinical success, strategic clarity, and financial stability makes SEP-631 a compelling investment opportunity with significant upside potential.

Keywords

SEP-631, MRGPRX2, Negative Allosteric Modulator, Mast Cell-Driven Diseases, Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Phase 1 Clinical Trial, Phase 2 Development, Biotechnology, GPCR, Native Complex Platform, Atopic Dermatitis, Interstitial Cystitis, Migraine, Asthma